Ondansetron oral spray - SUDA

Drug Profile

Ondansetron oral spray - SUDA

Alternative Names: Ondansetron lingual spray; Ondansetron OS; SUDA-002; Zensana; ZondaMist

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaDel Pharma
  • Developer SUDA
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postoperative-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Radiotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top